Create a free research account to view current pricing and place an order.
Mechanism of action
Retatrutide is a triple agonist acting through GLP, GIP, and glucagon receptor pathways. In addition to incretin-mediated satiety and glycemic signaling, glucagon receptor activity may support hepatic fatty-acid utilization and energy-expenditure signaling.
Half-life & pharmacokinetics
Half-life: Approx. 6 days; investigational.
Clinical research references commonly describe a weekly profile with an approximate half-life around 6 days. Human PK remains investigational compared with approved incretin drugs; conservative escalation and accumulation awareness are important.
Research dosing reference
1-12 mg once weekly; conservative escalation is strongly preferred.
Dose interpretation (U-100 units)
| Target dose | U-100 units |
|---|---|
| 1 mg | 20 units |
| 2 mg | 40 units |
| 4 mg | 80 units |
| 8 mg | 160 units |
Units are concentration-specific - confirm against your actual reconstitution volume.
Reconstitution & concentration
| Vial | Preferred reconstitution | Final concentration |
|---|---|---|
| 10 mg | 2 mL BAC Water | 0.050 mg/unit |
| 15 mg | 2 mL BAC Water | 0.075 mg/unit |
| 20 mg | 2 mL BAC Water | 0.100 mg/unit |
| 30 mg | 3 mL BAC Water preferred for dissolution and simplified concentration interpretation | 0.100 mg/unit |
| 60 mg | 3 mL BAC Water preferred for dissolution and simplified concentration interpretation | 0.200 mg/unit |
Injection timing
Once weekly on a consistent day. Time of day is less important than consistency; choose timing that minimizes nausea disruption.
Beginner escalation
Start at the lowest practical exposure and hold each step long enough to evaluate GI tolerance before increasing.
Side-effect mitigation
Monitor nausea, reflux, constipation, reduced appetite, hydration status, fatigue, and delayed gastric emptying. Slow escalation and hydration/electrolytes are primary mitigation tools.
Stack compatibility
Avoid stacking overlapping incretin agonists unless intentionally structured and clinician supervised. Pathway contrast with GH-axis, mitochondrial, or lipolysis adjuncts is generally cleaner than incretin overlap.
Storage & stability
Lyophilized: refrigerated or controlled cool storage. Reconstituted: refrigerated, protected from heat/light, and handled aseptically.
Protocol duration & reassessment
Investigational triple-agonist protocols should use extended stabilization periods between increases. Reassess every 8-12 weeks due to accumulation potential and overlapping GLP/GIP/glucagon signaling effects.
Frequently asked questions
What is Retatrutide and how does it work?
Retatrutide is a triple agonist acting through GLP, GIP, and glucagon receptor pathways. In addition to incretin-mediated satiety and glycemic signaling, glucagon receptor activity may support hepatic fatty-acid utilization and energy-expenditure signaling.
What is the half-life of Retatrutide?
Retatrutide: Approx. 6 days; investigational. Clinical research references commonly describe a weekly profile with an approximate half-life around 6 days. Human PK remains investigational compared with approved incretin drugs; conservative escala
How is Retatrutide reconstituted for research?
Preferred reconstitution for the 10 mg vial is 2 mL BAC Water, giving 0.050 mg/unit. Always confirm concentration math before any use. Research use only.
Is Retatrutide FDA approved?
No. Retatrutide is an investigational research-use-only compound - not for human or animal consumption and not FDA approved.
All research reference · Research guides
External references: Peptide (Wikipedia) · U.S. Food and Drug Administration